German cannabis prescriptions strictly limited by ‘disturbing’ court ruling

A decision by Germany’s Federal Social Court limiting the prescribing and insurance payment for medical cannabis has been described by a leading lawyer on cannabis issues as “disturbing”.

The court ruled that health insurance companies may only approve the prescription of medical cannabis to treat serious illnesses if the treating doctor has made a “careful and comprehensive assessment”. This includes analysing alternative therapies, whether drug addiction conflicts with the prescription of cannabis, the chances of success and the risks.

Read full article
I'm already a subscriber
Author default picture

CannIntelligence

This article was written by one of CannIntelligence’s international correspondents. We currently employ more than 40 reporters around the world to cover individual cannabis and cannabinoid markets. For a full list, please see our Who We Are page.

Our Key Benefits

The global cannabis market is in an opaque regulatory environment that requires professionals to be on top of industry developments to make informed decisions and optimise their strategy.

CannIntelligence provides organisations with leading market and regulatory data analysis to anticipate and understand market developments globally and the impact of regulatory changes to the business.

  • Stay informed of any legal and market change in the sector that impacts your organisation
  • Maximise resources by getting market and legal data analysis daily in one place
  • Make smart decisions by understanding how the regulatory and market landscape evolves
  • Anticipate risks in your decisions by monitoring regulatory changes that impact your organization